Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-392-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral: The acute oral median lethal dose (LD50) of the test item in the Sherman-Wistar strain rat was found to be greater than 2000 mg/kg bodyweight (LD50 > 16000 mg/kg bw)
Dermal: The acute dermal median lethal
dose (LD50) of the test item in the Wistar strain rat was found to be
greater than 2000 mg/kg bodyweight.
Inhalation: There will be no exposure to the test material via the inhalation route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1980-12-10 to 1980-12-31
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Protocol that complies with scientifically accepted methods, and is sufficiently detailed.
- Qualifier:
- according to guideline
- Guideline:
- other: Section 772.112-21 CFR 40.
- Deviations:
- no
- Principles of method if other than guideline:
- Five groups of five male albino rats were administered with single dose of 1,000, 2,000, 4,000, 8,000 and 16,000 mg/kg bw and observed for 14 days period during which time the rats were observed for signs of toxicity and mortalities.
- GLP compliance:
- no
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Sherman-Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
Source: No data available.
Age at study initiation: No data available.
Weight at study initiation: average weight between 200~300 g.
Fasting period before study: Feed was withheld overnight prior to dosing.
Housing: No data available.
Diet: ad libitum
Water: ad libitum
Acclimation period: No data available.
ENVIRONMENTAL CONDITIONS
Temperature (°C): No data available.
Humidity (%):No data available.
Air changes: No data available.
Photoperiod: No data available. - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 1,000, 2,000, 4,000, 8,000 and 16,000 mg/kg bw
- No. of animals per sex per dose:
- 5/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: No data available.
- Necropsy of survivors performed: Gross necropsies were performed. - Statistics:
- None
- Preliminary study:
- Not applicable
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 16 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One death occurred after 5-6 h in the 16,000 mg/kg bw dose group and no mortality in the remaining groups.
- Clinical signs:
- other: - There were no unusual behavioral signs noted at 1000, 2000 and 4000 mg/kg bw. - After 2 h, the animals appeared lethargic and ruffled; they appeared normal within 24 h. - After 1-2 h, the animals were depressed, ruffled and dirty. One death occurred a
- Gross pathology:
- No gross abnormalities were noted in all animals.
- Other findings:
- None
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The test article when administered to male Sherman-Wistar rats, had an acute oral LD50 of higher than 16,000 mg/kg bw.
- Executive summary:
Test Guidance
According to US EPA Section 772.112-21 CFR 40.
Method and material
A single dose of the undiluted test material was administered intragastrically to 5 groups of fasted male albino rats (Sherman-Wistar strain) at each treatment level (1,000, 2,000, 4,000, 8,000, and 16,000 mg/kg bw). The animals were observed for signs of toxicity or behavioral changes during the 14 day observation period. Individual weights were recorded on the day of dosing and at termination.
Results
There were no unusual behavioral signs noted at 1000, 2000 and 4000 mg/kg bw. After 2 h, the animals appeared lethargic and ruffled; they appeared normal within 24 h. After 1-2 h, the animals were depressed, ruffled and dirty. One death occurred after 5-6 h. Within 24 h the condition of the surviving animals had improved. They appeared essentially normal after 48 h. One death occurred after 5-6 h in the 16,000 mg/kg bw dose group and no mortality in the remaining groups. Gross autopsies were performed and nothing remarkable was revealed. The oral LD50 value of test material in rats has been determined to be higher than 16,000mg/kg bw.
Conclusion
In accordance with EU CLP (Regulation (EC) No. 1272/2008), classification is not required.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012-08-08 to 2012-08-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8 to 12 Weeks
- Weight at study initiation: 200 g
- Fasting period before study: None
- Housing: Suspended solid floor polypropylene cages furnished with woodflakes.
- Water: Mains drinking water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25 °C
- Humidity (%): 30-70 %
- Air changes (per hr): at least 15 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours continuous light/dark cycle - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Back and flanks
- % coverage: ca. 10% of the total body surface area
- Type of wrap if used: Self-adhesive bandage
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Cotton wool moistened with arachis oil BP to remove any residual test item.
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Concentration (if solution): N/A
- Constant volume or concentration used: yes
- For solids, paste formed: N/A
VEHICLE
- Amount(s) applied (volume or weight with unit):N/A
- Concentration (if solution):N/A
- Lot/batch no. (if required): N/A
- Purity: N/A - Duration of exposure:
- 24 h
- Doses:
- Single dose level of 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing and subsequently once daily for 14 days. Animals were weighed on Days 0, 7 and 14
- Necropsy of survivors performed: Yes, At the end of the study the animals were killed by cervical dislocation.
- Other examinations performed: Clinical signs, body weight, dermal reaction - Statistics:
- Using the mortality data obtained, an estimate of the acute dermal median lethal dose (LD50) of the test material was made.
- Preliminary study:
- Not applicable.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Remarks on result:
- other: no mortality was observed.
- Mortality:
- No mortality was observed.
- Clinical signs:
- other: There were no signs of systemic toxicity.
- Gross pathology:
- No abnormalities were noted at necropsy
- Other findings:
- - Organ weights: No data available
- Histopathology: No data available
- Potential target organs: No data available
- Other observations: No data available - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the test conditions, the acute dermal LD50 of test item is higher than 2000 mg/kg bw in rats therefore it is not classified according to CLP Regulation (EC) N° (1272-2008).
- Executive summary:
Test Guidance
Performed according to OECD Guideline 402
Method and materials
A group of Wistar (RccHan:WIST) rats (5/sex/dose) was given a single dermal application of test item at 2000 mg/kg bw. The test item was placed directly on back and flanks of the skin representing approximately 10 % of the total body surface of the animals. The test site was then covered by a semiocclusive dressing for 24 hours. Animals were then observed for mortality, clinical signs and bodyweights for 14 days and were all sacrificed for macroscopic examination.
Results
No mortality and no clinical signs were observed during the study. There were no signs of dermal irritation. One female showed no gain in bodyweight during the first week but expected gain in bodyweight during the second week. One other female showed expected gain in bodyweight during the first week but bodyweight loss during the second week. Remaining animals showed expected gains in bodyweight over the study period. No macroscopic abnormalities were observed at necropsy. The combined dermal LD50 of test item was considered to be higher than 2000 mg/kg bw in rats.
Conclusion
Under the test conditions, the acute dermal LD50 of test item is higher than 2000 mg/kg bw in rats therefore it is not classified according to CLP Regulation (EC) N° (1272 -2008).
Reference
Table1: Individual bodyweights and weekly bodyweight changes
Dose level (mg/kg bw) |
Animal no. and sex |
Body weight (g) at Day |
Body weight (g) during Week |
|||
0 |
7 |
14 |
1 |
2 |
||
2000 |
1-0 M |
336 |
343 |
365 |
7 |
22 |
1-1 M |
318 |
333 |
358 |
15 |
25 |
|
1-2 M |
315 |
323 |
335 |
8 |
12 |
|
1-3 M |
295 |
311 |
325 |
16 |
14 |
|
1-4 M |
336 |
345 |
368 |
9 |
23 |
|
2-0 F |
216 |
220 |
214 |
4 |
-6 |
|
2-1 F |
230 |
235 |
236 |
5 |
1 |
|
2-2 F |
228 |
229 |
236 |
1 |
7 |
|
2-3 F |
224 |
226 |
228 |
2 |
2 |
|
2-4 F |
220 |
220 |
226 |
0 |
6 |
Table 2: Dermal irritation observations
Animal Number |
Observation |
Day |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
Male 1-0 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Male 1-1 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Male 1-2 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Male 1-3 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Male 1-4 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Female 2-0 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Female 2-1 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Female 2-2 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Female 2-3 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Female 2-4 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Oral
In a key study performed according to US EPA Section 772.112-21 CFR 40asingle dose of the undiluted test material was administered intragastrically to 5 groups of fasted male albino rats (Sherman-Wistar strain) at each treatment level (1,000, 2,000, 4,000, 8,000, and 16,000 mg/kg bw). The animals were observed for signs of toxicity or behavioural changes during the 14 day observation period.
There were no unusual behavioral signs noted at 1000, 2000 and 4000 mg/kg bw. After 2 h, the animals appeared lethargic and ruffled; they appeared normal within 24 h. After 1-2 h, the animals were depressed, ruffled and dirty. One death occurred after 5-6 h. Within 24 h the condition of the surviving animals had improved. They appeared essentially normal after 48 h. One death occurred after 5-6 h in the 16,000 mg/kg bw dose group and no mortality in the remaining groups. Gross autopsies were performed and nothing remarkable was revealed. The oral LD50 value of test material in rats has been determined to be higher than 16,000mg/kg bw.
Dermal
In a key study performed according to OECD Guideline 402 agroup of Wistar rats (5/sex/dose) was given a single dermal application of test item at 2000 mg/kg bw. The test item was placed directly on back and flanks of the skin representing approximately 10 % of the total body surface of the animals. The test site was then covered by a semio-cclusive dressing for 24 hours.
No mortality and no clinical signs were observed during the study. There were no signs of dermal irritation. One female showed no gain in bodyweight during the first week but expected gain in bodyweight during the second week. One other female showed expected gain in bodyweight during the first week but bodyweight loss during the second week. Remaining animals showed expected gains in bodyweight over the study period. No macroscopic abnormalities were observed at necropsy. The combined dermal LD50 of test item was considered to be higher than 2000 mg/kg bw in rats.
Inhalation
According to REACH Annex XIII Section 8.5 information on acute toxicity will be provided for at least one other route in addition to the oral route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. The substance is a waxy hydrophobic solid with a vapour pressure of 0.009 Pa at 25 °C and is used in lubricants by workers and consumers. It is expected that inhalation exposure from these uses will be low and that the most likely route of exposure for workers and consumers is the dermal route. Testing for acute toxicity via the inhalation route is, therefore, not required.
Justification for classification or non-classification
Under the test conditions, the acute oral and dermal LD50 of test item are higher than 2000 mg/kg bw in rats therefore it is not classified according to CLP Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.